A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19

Authors:

Dr Fasihul Khan. Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK

Dr Iain Stewart. Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK

Dr Laura Fabbri. Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK

Samuel Moss, Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK

Professor Karen A. Robinson. John Hopkins University

Professor Alan Smyth. Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Nottingham, UK

Professor Gisli Jenkins. Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK

Correspondence to:

Dr Fasihul Khan fasihul.khan@nottingham.ac.uk

Total word count: 3246

PROSPERO registration number: CRD42020176375

Date of registration: 25th March 2020

ABSTRACT

Background

There is accumulating evidence for an overly activated immune response in severe Covid-19. Several studies exploring the role of immunomodulation as a potential therapeutic strategy have been published. Through systematic review and meta-analysis, we assess the effectiveness of specific interleukin inhibitors for the treatment of Covid-19.

Methods

Electronic databases, preprint servers and clinical trial registries were searched on 23rd October 2020 to identify studies of immunomodulatory agents (anakinra, sarilumab, siltuximab and tocilizumab) for the treatment of Covid-19. The primary outcomes were severity on an ordinal scale measured at day 15 and days to hospital discharge. Key secondary endpoints included overall mortality.

Results

Sixty studies totalling 16588 patients were included, four were randomised controlled studies. Most explored outcomes in patients who received tocilizumab (50/60), followed by anakinra (5/60), sarilumab (4/60) and siltuximab (1/60). There was substantial heterogeneity in meta-analysis and pooled effect estimates should be interpreted with caution. In retrospective studies, tocilizumab was associated with less severe outcomes on an ordinal scale (Generalised odds ratio 1.23 95%CI 1.10;1.37, I^2=97%) and reduced

mortality (HR 0.58 95%CI 0.43;0.78, I^2=80.3%) but consistent outcome benefit was not shown in prospective studies. The mean difference with control in the duration of hospitalisation was 0.26 days (95%CI -0.10;0.62, I^2=85%). Insufficient data precluded meta-analysis for other immunomodulatory agents.

Conclusion

Meta-analysis revealed substantial heterogeneity in reported findings of tocilizumab and an inconclusive effect from prospective studies. Currently available evidence for the efficacy of anakinra, siltuximab or sarilumab in Covid-19 is insufficient. Results from adequately powered, high-quality randomised studies are urgently needed.

INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China in December 2019(1). Since then, coronavirus disease 2019 (Covid-19) has been declared a global pandemic by the World Health Organisation (WHO) and continues to spread at an exponential rate with over a million deaths currently reported worldwide (2, 3).

The clinical manifestations of Covid-19 tend to be heterogenous ranging from asymptomatic infection to acute respiratory disease syndrome (ARDS), multi-organ failure and death. Mechanisms underlying severe disease are incompletely understood, but accumulating evidence points towards a dysregulated and excessive host immune response referred to as cytokine storm syndrome (CSS)(4). During this state of immunological hyperactivation, increased circulating levels of pro-inflammatory cytokines including interleukin (IL)-1 and IL-6 have been demonstrated, and are associated with adverse clinical outcomes (5-7). Suppression of pro-inflammatory cytokines in Covid-19 may therefore be a potential therapeutic strategy (8).

SARS-CoV-2 shares a number of genetic and clinical similarities with other zoonotic coronaviruses, including severe acute respiratory syndrome coronavirus (SARS) and Middle East respiratory syndrome (MERS)(9, 10). There are also reports of elevated pro-inflammatory cytokines in patients with SARS and MERS (11, 12), suggesting overlapping therapeutic targets in the management of SARS, MERS and Covid-19.

Several clinical studies evaluating the role of immunomodulatory agents in Covid-19 have been published recently. Through systematic review and critical appraisal of the literature, we assess the effectiveness and safety of specific IL-1 (anakinra) and IL-6 (tocilizumab, siltuximab, sarilumab) inhibitors for the treatment of Covid-19, whilst concurrently drawing on literature from previous similar coronavirus infections (SARS and MERS). These agents already carry approval for the treatment of other rare non-infectious and autoimmune conditions, with an acceptable safety profile.

METHODS

The systematic review was conducted in accordance with a pre-specified protocol (PROSPERO registration number: CRD42020176375), and has been reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines(13).

Search strategy and study selection

Electronic database searches were carried out in MEDLINE (1946 to latest) and EMBASE (1974 to latest), and ongoing clinical trial registries (clinicaltrials.gov, EU Clinical Trials Register and the Chinese Clinical Trial Registry), with the last search carried out on 23rd October 2020. Search terms were kept broad and included keywords and controlled vocabulary for patient and treatment-related terms (see supplementary appendix for MEDLINE search strategy). Unpublished and ongoing studies were identified by searching pre-print servers including medRxiv and bioRxiv. Searches were carried out independently

by two reviewers in a standardised manner, followed by screening through titles and abstracts, before full text review. Disagreements were resolved by consensus, with unresolved conflicts decided by a third reviewer.

The review included all original studies excluding case reports, evaluating the use of at least one of anakinra, tocilizumab, sarilumab or siltuximab in patients aged over 18 with either suspected or confirmed Covid-19, SARS or MERS. Retrospective studies without a comparator arm were excluded due to their associated heterogeneity and inherent risk of bias. Language or year of publication restrictions were not applied. No minimal study sample size was specified for inclusion.

The planned primary outcomes were selected based on their clinical usefulness and included time to hospital discharge (days) and severity on an adapted four-point ordinal scale at day 15 with the following ratings: i) death; ii) requirement for invasive mechanical ventilation (IMV) or ECMO; iii) hospitalised but no requirement for IMV/ECMO; iv) not hospitalised. Secondary outcomes included time to clinical improvement (days), duration of mechanical ventilation (days), overall mortality, mortality at 28 days and treatment related adverse events.

Data extraction and risk of bias assessment

Data were extracted from article text and figures using a data-extraction proforma and verified by a second reviewer. Information sought included study design, sample size, participant demographics, clinical investigation findings, intervention characteristics (name

of agent, dose, route), treatment related adverse events, requirement and duration of invasive and non-invasive ventilation, use and dosage of oxygen, duration of hospital stay, survival outcome measures and follow up duration. Where ordinal outcomes were reported at multiple timepoints, those closest to day 15 were chosen for extraction. For ongoing trial protocols, the registration number, sample size, and expected date of completion were recorded.

Risk of bias assessment was carried out independently in duplicate. Due to the heterogeneity of study designs included in the review, various quality assessment tools available through the National Institute of Health were applied(14). The tools assess risk of bias through criterion specific to each study design, before providing an overall quality rating of good, fair or poor. Randomised studies were assessed using the Cochrane risk-of-bias tool for randomised trials (RoB2)(15). As per the review protocol, all studies were included irrespective of their risk of bias rating.

Statistical analysis

All identified studies were included in the narrative summary with summary tables for characteristics. For the primary outcomes, numbers of individuals meeting each outcome on the adapted ordinal scale were pooled using rank-based Wilcoxon Mann Whitney tests with ties split evenly between positive and negative outcomes, providing a generalised odds ratio (GenOR) with 95% confidence intervals (CI). The GenOR provides a measure of the likelihood that the intervention leads to a better rather than worse outcome when compared to a randomly chosen control (16). Mean hospital duration and standard

deviation (SD) were extracted or were estimates from median and range/interquartile range (IQR) using the Box-Cox method (17). Mean difference in hospital stay was calculated where a control arm was reported. Where available, adjusted hazard ratios (HR) and unadjusted mortality data were extracted for quantitative synthesis. Where data were not reported in a tabular format, values were extracted from plotted data using a digital plot analyser(18).

Where sufficient studies were identified for a specific immunomodulator, findings were assessed using random effects meta-analysis and presented as forest plot. Limited study numbers precluded subgroup analysis by immunomodulator. Meta-analyses were grouped by retrospective and prospective design and presented on the same plots with no overall estimate. The I^2 statistic was used to evaluate statistical heterogeneity. Although sample sizes were limited, we used pseudo-R^2 from meta-regression to explore variability in heterogeneity owing to study design (single-centre vs. multicentre), non-peer reviewed manuscripts, use of concomitant steroids, route of drug administration and day outcome measured. Publication bias was assessed using funnel plot analysis and Egger's test. All analyses were performed using Stata v.16 (StataCorp, College Station, TX, USA).

RESULTS

Search of the electronic databases (MEDLINE and EMBASE) on 23rd October yielded a total of 2275 studies, with a further 572 studies identified through preprint servers. Following removal of duplicates, screening and full text review, 60 articles published worldwide were shortlisted for inclusion (anakinra, n=4; tocilizumab, n=50; anakinra and tocilizumab, n=1; sarilumab, n=4; siltuximab, n=1) (Figure 1). 43 studies were published in peer-reviewed

journals, with the remaining 17 identified through preprint servers. All studies were performed in patients with Covid-19, with no suitable studies identified for SARS or MERS. Twenty-four studies were prospective in design, with thirteen studies including a control group for comparison, of which four were randomised studies. The remaining 36 studies were retrospective case-control studies. Included studies provided a total of 16588 patients, of which 5632 (34%) received one of the therapies under review alongside standard of care (SOC), and 10956 (59%) received SOC alone. Individual study characteristics for the published studies are presented in Tables 1 and 2.

Risk of bias assessment of the retrieved studies identified multiple limitations and highlighted a number of biases (Figure 2). The majority of included studies defined the study population specifically with clear inclusion/exclusion criteria. Where applicable, control participants were selected from the same population. However, many studies provided insufficient detail of the interventions and outcomes being studied or reporting was inconsistent, with key design, and outcome details omitted. Statistical analysis was variably reported, with few studies providing a sample size justification. In nearly all studies, patients were on concomitant therapies, limiting the ability to discern whether a specific intervention was related to the outcome. Following a formal risk of bias assessment, 16 (27%) studies were rated as good, 35 (58%) fair and 9 (15%) poor. Publication bias, assessed by observation of funnel plots and Egger's test, was not present for any of the outcomes assessed (Supplementary Appendix)

Tocilizumab

Nine prospective studies with a control arm, eight prospective studies without a control arm, and 34 case-control studies examining the clinical impact of tocilizumab in Covid-19 were identified. Amongst the prospective studies there were four randomised clinical trials (RCTs). In total, the studies reported outcomes from 15947 patients, of whom 5119 (32%) were given tocilizumab. Criteria for eligible participants varied across the studies, with many specifying respiratory failure with laboratory evidence of hyperinflammation as a prerequisite. The dose of tocilizumab administration was not entirely consistent with intravenous 8mg/kg or 400mg the most commonly studied route and dose.

Ordinal scale

A total of 12 studies provided outcomes on an adapted 4-point scale for 1782 patients including cases and controls. The median time for reporting outcomes after treatment was 14 days (IQR 14-28). In two of the three RCTs, tocilizumab was associated with improved outcomes compared with controls who received SOC alone(19, 20). When prospective studies were included in meta-analysis (Figure 3), tocilizumab was not associated with better outcomes (GenOR 1.09 95% CI 0.99;1.19, I^2 = 84.3%). Variability in reported concomitant steroid administration had a significant contribution upon the substantial heterogeneity observed (Supplementary Appendix). When retrospective studies were included in meta-analysis, tocilizumab was associated with better outcomes, indicating a 23% greater chance of less-severe outcomes on the adapted ordinal scale when compared to control (GenOR 1.23 95% CI 1.10;1.37, I^2 = 97%). However, these results should be

interpreted with caution as there was substantial heterogeneity which could not be explained by variability in the factors assessed.

Duration of hospitalisation

Eight retrospective case-control studies and one RCT reported the duration of hospitalisation for a total of 699 survivors who received tocilizumab (Figure 4). Case-control studies reporting the duration of hospitalisation were combined to give an overall summary estimate (20.55 days 95%CI 15.68;25.48, I^2 = 96.5%), which was lower than the duration reported by the RCT (22.31 days 95%CI 21.38;23.26). Compared with 446 patients who received SOC only, the difference in the mean duration of hospital stay 0.26 days (95% CI -0.10;0.62, I^2 = 85.9), with considerable heterogeneity. Variability in route of administration was associated with heterogeneity (R^2 = 94.4%, p<0.001).

Overall mortality

Seventeen studies totalling 10,159 patients reported adjusted hazard ratios for overall mortality, at a follow up time censored at a median of 28 days (IQR 14-30). Amongst the studies, two were RCTs and neither found any difference between tocilizumab and control for mortality (19, 21). Survival benefit was not conclusively demonstrated in prospective studies (HR 0.63 95%CI 0.36;1.10, I^2 = 13%) (Figure 5). In the remaining retrospective case-control studies, tocilizumab was associated with a 42% lower risk of adjusted mortality with substantial heterogeneity (HR 0.58 95%CI 0.43;0.78, I^2 = 80.3%;). Although meta-regressions

did not identify a significant contribution to heterogeneity, variability was noted according to peer review (R^2 = 86.9%) and outcome day (R^2 = 30.9%).

Rate ratios (RR) were calculated from 31 studies, including three RCTs, reporting unadjusted mortality data for 10,564 patients at a median follow up of 18 days (IQR 9-28) (Figure 6). Tocilizumab was associated with a 25% reduced risk of mortality compared with the control arm in retrospective studies (RR 0.75 95%CI 0.61;0.94, I^2 = 81.3%). Heterogeneity was substantial and was significantly associated with variability in the time at which the outcome was recorded. Tocilizumab was not associated with reduced mortality in the prospective studies (RR 0.73 95%CI 0.32;1.62, I^2 = 39.1%).

Other immunomodulators

Studies exploring outcomes in patients who received anakinra, sarilumab or siltuximab were not quantitively synthesised, owing to differences in outcomes reported, study design and limited study numbers. Similar to studies in tocilizumab, participant criteria were inconsistent but typically included patients with respiratory failure and signs of hyperinflammation. Doses of therapeutic agents ranged from 200-600mg daily for anakinra, and 200-400mg daily for sarilumab. In all studies, patients received concomitant medications including but not limited to antivirals, hydroxychloroquine and corticosteroids. Meta-analysis inclusive of all immunomodulatory agents without sub analysis are presented in Supplementary Figures 5-8.

Anakinra

Two prospective studies and three retrospective case-control exploring outcomes in 139 patients who received anakinra and 1575 controls were retrieved. Two case-control studies reported ordinal outcome data for both anakinra and control participants. Anakinra was associated with improved clinical outcomes on day 15 in a study of 22 patients (GenOR 4.00 95%CI 2.39;6.89)(22), and in another study of 45 patients on day 21 (GenOR 1.50 95%CI 1.20;1.88)(23). In the only study reporting adjusted HRs, treatment in 37 patients was not associated with a mortality benefit (aHR 0.40 95%CI 0.13;1.28)(24). In a further study reporting unadjusted HRs, anakinra administered to 52 patients was associated with a reduced risk of death (HR 0.30; 95%CI 0.12-0.71)(25). Across the remaining three studies(22, 23, 26), there was a combined case fatality rate (CFR) of 6% (3/50) in participants who received anakinra, compared with 30.8% (8/26) in two studies reporting mortality outcomes from controls(22, 23). No studies compared the duration of hospitalisation between recipients and non-recipients of anakinra.

Sarilumab

Four prospective studies of sarilumab with a total sample size of 372 participants were included. In the only study reporting ordinal outcomes and duration of hospitalisation(27), sarilumab was not associated with improved outcomes when measured on day 28 (GenOR 1.07 95%CI 0.90;1.27), whilst the duration of hospitalisation was comparable amongst treated and non-treated patients (mean difference 0.02; 95%CI -0.51;0.54). All studies reported mortality outcomes, including one study reporting the adjusted HR. When

sarilumab was given to 28 patients no effect on mortality was observed (aHR 0.36 95%CI 0.08;1.68)(27). The combined CFR across the three remaining studies was 9.8% (31/316)(28-30). No control mortality data was available.

Siltuximab

A single prospective cohort study of siltuximab studying outcomes in 60 patients was identified(31). Neither ordinal outcome data nor duration of hospitalisation were reported, but the adjusted risk of mortality was significantly lower in patients who received siltuximab (aHR 0.46 95%CI 0.22;0.97).

Treatment related adverse events

Many studies did not report treatment related adverse events, but where described (41% of studies), adverse events typically included secondary bacterial infections and derangement of liver enzymes (Table 3). In studies with a comparator arm exploring outcomes from patients who received anakinra or sarilumab, the frequency of treatment related adverse events was similar in both treatment and comparator groups. Findings from studies reporting outcomes following tocilizumab administration were inconsistent. In four studies (21%), tocilizumab recipients had an increased prevalence of secondary infections compared with controls. However, in twelve studies (63%), tocilizumab was associated with a lower or similar rate of secondary infections when compared with controls.

Clinical trials

Sixty-one planned or in-process clinical trials (tocilizumab, 43; siltuximab, 4; sarilumab, 8; anakinra, 13) were identified through clinical registry searches, with some clinical trials exploring more than one immunomodulatory agent. Currently registered clinical trials and their estimated dates of completion are provided in the supplementary appendix.

DISCUSSION

In this systematic review and meta-analysis, we summarise and examine the association between immunomodulatory agents and multiple outcomes in Covid-19. Although there was substantial heterogeneity across tocilizumab studies exploring outcomes on an adapted four-point ordinal scale, a beneficial effect of tocilizumab compared with controls was suggested in retrospective studies, and whilst prospective studies followed a similar direction of association, findings were not conclusive. The certainty of the findings related to the adapted ordinal severity scale are assessed as moderate using GRADE(32). The mean duration of hospitalisation was not altered by intervention, with low certainty of findings. When mortality was examined specifically, a survival benefit with tocilizumab was noted in retrospective studies, although high heterogeneity was demonstrated. Amongst prospective studies, there was less heterogeneity, and although a clear association was not observed, the estimates were inconclusive with wide confidence intervals, suggesting larger sample sizes are needed to better inform this question. Consequently, we assess the certainty of our findings related to overall mortality as moderate.

Due to heterogeneity in study designs and reported outcomes, there was insufficient data for quantitative analysis in non-tocilizumab studies. Anakinra, in two small case-control studies was associated with improved ordinal outcomes. However, in the only study reporting adjusted HRs, no mortality benefit with anakinra was reported. In unadjusted analyses, when mortality was pooled across studies, recipients of anakinra had a CFR of 6% compared with 30.8% in controls where reported. Sarilumab in four observational studies was not associated with improved ordinal outcomes, shortened duration of hospitalisation, or improved mortality. Only one study reporting siltuximab was identified, and neither ordinal outcome data nor hospitalisation were reported, but mortality was significant lower in patients who received intervention. For all included agents, no specific adverse events were consistently reported across the studies. No suitable studies in SARS or MERS were found. Sixty-one registered clinical trials exploring immunomodulatory agents in Covid-19 were identified, of which some have completed and been published.

In this review we highlight multiple limitations and considerable sources of inter-study heterogeneity. The majority of included studies were non-randomised cohorts of relatively modest size. Although most studies necessitated respiratory failure requiring at least basic respiratory support, participant criteria were not entirely consistent across the studies. The dosage and delivery of therapy varied across many of the non-randomised studies, and in nearly all studies patients were on concomitant medications such as antivirals, hydroxychloroquine and steroids with administration at the discretion of the treating physician, precluding causal associations of specific interleukin inhibitors with outcomes. Study outcomes were heterogeneous and a combination of clinical, laboratory and

radiological outcomes were reported, rather than a single consistent endpoint. Furthermore, there was inconsistency in the duration of follow up and timing of reported outcomes. Individual patient data (IPD) may have mitigated some of these limitations, but in a rapidly progressing area, seeking IPD was deemed to be unrealistic due to the associated delays. Lastly, there was significant statistical heterogeneity as measured by the I^2, and therefore the findings of our meta-analysis should be interpreted with caution. We were unable to explain all the residual heterogeneity using the factors we assessed, although concomitant steroid use, route of drug administration and day of outcome measure appeared to contribute within specific outcomes.

To maximise value and timeliness of our review of four specific immunomodulators, two primary endpoints and a number of secondary endpoints, we included both retrospective and preprint studies. Risk of bias was minimised by restricting analysis of non-prospective studies to those with a control group, and caution is used to present summaries separately. We did not detect any heterogeneity owing to inclusion of non-peer reviewed studies, and no significant publication bias was observed in the reporting of effects. Where there was insufficient data for meta-analysis, summary outcomes were presented with qualitative synthesis to ensure the review was comprehensive. The data presented here represent findings from different countries, offering diversity in ethnic background.

In conclusion, this systematic review provides the most up-to-date and complete evidence for a range of specific immunomodulatory therapies in the management of Covid-19. We demonstrate through quantitative synthesis of retrospective studies in tocilizumab that intervention was frequently associated with improved outcomes yet there was no

difference in the duration of hospitalisation or all-cause mortality. However, data were highly heterogeneous and must be interpreted with caution. In contrast, prospective studies showed potential association with inconclusive estimates, indicating further prospective studies are required. This review further establishes evidence that the efficacy of anakinra, siltuximab or sarilumab in Covid-19 is currently insufficient and adequately powered high-quality randomised clinical studies are urgently needed.

Funding: FK/LF/IS/AS are supported by the Nottingham National Institute for Health Research (NIHR) Biomedical Research Centre. RGJ is supported by an NIHR Research Professorship (RP-2017-08-ST2-014).

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506.
2. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 2020 [Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
3. Johns Hopkins University of Medicine
COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirusjhuedu/maphtml.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033-4.
5. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
6. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020:2020.03.30.20048058.
7. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-9.
8. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2).
9. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020;48(2):155-63.
10. Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-6.
11. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103.
12. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13.
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.
14. National Heart L, National Institute of Health. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools [
15. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.

16. Churilov L, Arnup S, Johns H, Leung T, Roberts S, Campbell BCV, et al. An Improved Method for Simple, Assumption-Free Ordinal Analysis of the Modified Rankin Scale Using Generalized Odds Ratios. International Journal of Stroke. 2014;9(8):999-1005.
17. McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Statistical Methods in Medical Research. 2020;29(9):2520-37.
18. WebPlotDigitizer. https://apps.automeris.io/wpd/ [
19. Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine. 2020.
20. Rosas I, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia. medRxiv. 2020:2020.08.27.20183442.
21. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine. 2020.
22. Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proceedings of the National Academy of Sciences. 2020;117(32):18951-3.
23. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology. 2020;2(6):e325-e31.
24. Narain S, Stefanov D, Chau AS, Weber AG, Marder GS, Kaplan B, et al. Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 'Cytokine Storm': A Retrospective Observational Cohort Study. medRxiv. 2020:2020.06.16.20126714.
25. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatology. 2020;2(7):e393-e400.
26. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Annals of the rheumatic diseases. 2020;79(10):1381-2.
27. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study. Annals of the rheumatic diseases. 2020;(no pagination).
28. Benucci M, Giannasi G, Cecchini P, Gobbi FL, Damiani A, Grossi V, et al. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients. Journal of Medical Virology. 2020.
29. Gremese E, Cingolani A, Bosello SL, Alivernini S, Tolusso B, Perniola S, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine.
30. Sinha P, Mostaghim A, Bielick CG, McLaughlin A, Hamer DH, Wetzler LM, et al. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. International Journal of Infectious Diseases. 2020;99:28-33.
31. Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv. 2020:2020.04.01.20048561.

32. Granholm A, Alhazzani W, Møller MH. Use of the GRADE approach in systematic reviews and guidelines. British Journal of Anaesthesia. 2019;123(5):554-9.
33. Albertini L, Soletchnik M, Razurel A, Cohen J, Bidegain F, Fauvelle F, et al. Observational study on off-label use of tocilizumab in patients with severe COVID-19. European Journal of Hospital Pharmacy Science & Practice. 2020;10:10.
34. Antony SJ, Davis MA, Davis MG, Almaghlouth NK, Guevara R, Omar F, et al. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. Journal of Medical Virology. 2020;09:09.
35. Campins L, Boixeda R, Perez-Cordon L, Aranega R, Lopera C, Force L. Early tocilizumab treatment could improve survival among COVID-19 patients. Clinical and experimental rheumatology. 2020;38(3):578.
36. Carvalho V, Turon R, Goncalves B, Ceotto V, Kurtz P, Righy C. Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study. medRxiv. 2020:2020.07.13.20149328.
37. Dastan F, Saffaei A, Haseli S, Marjani M, Moniri A, Abtahian Z, et al. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. International Immunopharmacology. 2020;88 (no pagination).
38. Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javad-Mousavi SA, et al. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. International Immunopharmacology. 2020;89:107102.
39. Mikulska M, Nicolini LA, Signori A, Di Biagio A, Sepulcri C, Russo C, et al. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS ONE [Electronic Resource]. 2020;15(8):e0237831.
40. Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. European Journal of Internal Medicine. 2020;76:36-42.
41. Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial. medRxiv. 2020:2020.06.01.20119149.
42. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine. 2020.
43. Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, Fernandez-Hidalgo N, Perez-Hoyos S, Salvador F, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. medRxiv. 2020:2020.05.07.20094599.
44. Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clinical and experimental rheumatology. 2020;38(3):529-32.
45. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, et al. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020:2020.07.20.20157503.
46. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews. 2020;19(7).

47. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology. 2020.
48. Canziani LM, Trovati S, Brunetta E, Testa A, De Santis M, Bombardieri E, et al. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Journal of Autoimmunity. 2020;(no pagination).
49. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. European journal of internal medicine. 2020;76:31-5.
50. De Rossi N, Scarpazza C, Filippini C, Cordioli C, Rasia S, Mancinelli CR, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine. 2020;25:100459.
51. Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C, Sonnerborg A, et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. Journal of Internal Medicine. 2020.
52. Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, et al. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2020.
53. Moreno Garcia E, Rico Caballero V, Albiach L, Aguero D, Ambrosioni J, Bodro M, et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv. 2020:2020.06.05.20113738.
54. Gokhale Y, Mehta R, Karnik N, Kulkarni U, Gokhale S. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia. EClinicalMedicine. 2020;24 (no pagination).
55. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology. 2020;2(8):e474-e84.
56. Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine.
57. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Internal Medicine. 2020.
58. Hill JA, Menon MP, Dhanireddy S, Wurfel MM, Green M, Jain R, et al. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature. medRxiv. 2020:2020.08.05.20169060.
59. Holt GE, Batra M, Murthi M, Kambali S, Santos K, Bastidas MVP, et al. Lack of tocilizumab effect on mortality in COVID19 patients. Scientific Reports. 2020;10(1):17100.
60. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PloS one. 2020;15(8 August).
61. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. EClinicalMedicine. 2020;24 (no pagination).

62. Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. MedRxiv : the Preprint Server for Health Sciences. 2020;12:12.
63. Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, et al. Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;12.
64. Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, Moreno S, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clinical Microbiology and Infection.
65. Patel K, Gooley TA, Bailey N, Bailey M, Hegerova L, Batchelder A, et al. Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients. Journal of Internal Medicine.n/a(n/a).
66. Pettit NN, Nguyen CT, Mutlu GM, Wu D, Kimmig L, Pitrak D, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. Journal of Medical Virology. 2020.
67. Potere N, Di Nisio M, Rizzo G, La Vella M, Polilli E, Agostinone A, et al. Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;05.
68. Ramaswamy M, Mannam P, Comer R, Sinclair E, McQuaid DB, Schmidt ML. Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study. medRxiv. 2020:2020.05.14.20099234.
69. Rodriguez-Bano J, Pachon J, Carratala J, Ryan P, Jarrin I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology & Infection. 2020;27:27.
70. Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM : monthly journal of the Association of Physicians. 2020;113(8):546-50.
71. Roomi S, Ullah W, Ahmed F, Farooq S, Sadiq U, Chohan A, et al. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. Journal of medical Internet research. 2020;22(9):e21758.
72. Rossi B, Nguyen LS, Zimmermann P, Boucenna F, Baucher L, Dubret L, et al. Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study. medRxiv. 2020:2020.06.06.20122341.
73. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. Journal of Infection. 2020;08:08.
74. ROUMIER M, PAULE R, GROH M, VALLEE A, ACKERMANN F. Interleukin-6 blockade for severe COVID-19. medRxiv. 2020:2020.04.20.20061861.
75. Ruiz-Antoran B, Sancho-Lopez A, Torres F, Moreno-Torres V, de Pablo Lopez de Abechuco I, Garcia Lopez P, et al. COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY. medRxiv. 2020:2020.09.07.20189357.

76. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;11.
77. Tsai A, Diawara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on mortality in severe COVID-19. medRxiv. 2020:2020.07.30.20114959.
78. Wadud N, Ahmed N, Mannu Shergil M, Khan M, Krishna MG, Gilani A, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. medRxiv. 2020:2020.05.13.20100081.
79. Zheng K-L, Xu Y, Guo Y-F, Diao L, Kong X-Y, Wan X-J, et al. Efficacy and safety of tocilizumab in COVID-19 patients. Aging. 2020;12(19):18878-88.



Figure 1 Flow diagram illustrates systematic search and screening strategy, including numbers meeting eligibility criteria and numbers excluded.

A. Randomised Controlled Trials
Randomised
Intervention assignment
Intervention adherence
Missing data
Outcome
Results
Overall risk of bias
0%
25%
50%
75%
100%
N/A
Good
Fair
Poor
B. Non-randomised prospective studies
1
2
3
4
5
6
7
8
9
10
11
12
13
14
0%
25%
50%
75%
100%
N/A
Yes
Cannot determine
No
C. Retrospective studies
1
2
3
4
5
6
7
8
9
10
11
12
0%
25%
50%
75%
100%
Yes
Cannot determine
No

Figure 2 – Summary of risk of bias assessment

A - Randomised clinical trials assessed using Cochrane risk of bias 2 tool. Risk of bias was assessed in six categories and scored as either low risk of bias, some concern, or high risk of bias, before an overall risk of bias was given to each study.

B - Non-randomised prospective studies. Questions numbered in the first column. 1. Was the research question or objective in this paper clearly stated? 2. Was the study population clearly specified and defined? 3. Was the participation rate of eligible persons at least 50%? 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? 5. Was a sample size justification, power description, or variance and effect estimates provided? 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 10. Was the exposure(s) assessed more than once over time? 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 12. Were the outcome assessors blinded to the exposure status of participants? 13. Was loss to follow-up after baseline 20% or less? 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

C - Summary of risk of bias assessment for case-control studies. Questions numbered in first column. 1. Was the research question or objective in this paper clearly stated and appropriate? 2. Was the study population clearly specified and defined? 3. Did the authors include a sample size justification? 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? 6. Were the cases clearly defined and differentiated from controls? 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? 8. Was there use of concurrent controls? 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? 11. Were the assessors of exposure/risk blinded to the case or control status of participants? 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?



Figure 3 – Tocilizumab generalised odds ratios (OR) for ordinal outcome forest plot. Generalised OR shown for each study with 95% confidence interval and day at which ordinal outcome recorded. Sample sizes given for patients receiving intervention (n) alongside total included (N) in study. Summary estimates presented separately for prospective and retrospective studies.

* non peer-reviewed preprint studies

randomised controlled trials



Figure 4 – Tocilizumab duration of hospitalisation (days) forest plot. **A**: Mean duration of hospital stay. **B**: Mean difference compared with controls in duration of hospital stay. Effect sizes and associated 95% confidence intervals presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies.

* non peer-reviewed preprint studies

\# randomised controlled trials



Figure 5 – Tocilizumab adjusted hazard ratios (HR) for overall mortality forest plot. Adjusted HRs with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included (N) in study. Summary estimates presented separately for prospective and retrospective studies.
* non peer-reviewed preprint studies
# randomised controlled trials
NR, not reported



Figure 6 – Tocilizumab mortality risk ratios (RR) forest plot. Risk ratios with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies.

* non peer-reviewed preprint studies

\# randomised controlled trials

NR, not reported

Author, year	Drug	N, Tx/Control	Study country	Centre	Study design	Author, year	N, Tx/Control	Drug	Study country	Centre	Study design	Author, year	N, Tx/Control	Drug	Study country	Centre	Study design
Aouba, 2020(26)	A	9/0	France	single centre	Prospective	*Rosas, 2020(20)	294/144	T	USA	multi-centre	Double blind RCT	Ip, 2020(33)	134/413	T	USA	multi-centre	Case-control
Huet, 2020(25)	A	52/44	France	single centre	Prospective with control	Salvarani, 2020(34)	60/63	T	Italy	multi-centre	Open label RCT	Kewan, 2020(35)	28/23	T	USA	single centre	Case-control
Cauchois, 2020(22)	A	12/10	France	multi-centre	Case-control	*Sanchez-Montalva, 2020(36)	82/0	T	Spain	single centre	Prospective	*Kimmig, 2020(37)	54/57	T	USA	single centre	Case-control
Cavalli, 2020(23)	A	29/16	Italy	single centre	Case-control	Sciascia, 2020(38)	63/0	T	Italy	multi-centre	Prospective	Klopfenstein, 2020(39)	20/25	T	France	single centre	Case-control
*Narain, 2020(24)	A/T	37/1505	USA	multi-centre	Case-control	Stone, 2020(21)	161/82	T	USA	multi-centre	Double blind RCT	Martinez-Sanz, 2020(40)	260/969	T	Spain	multi-centre	Case-control
Benucci, 2020(28)	Sa	8/0	Italy	single centre	Prospective	*Strohbehn, 2020(41)	32/41	T	USA	single centre	Phase 2 open label	Patel, 2020(42)	60/1505	T	USA	single-centre	Case-control
Della-Torre, 2020(27)	Sa	28/28	Italy	single centre	Prospective with control	Toniati, 2020(43)	100/0	T	Italy	single centre	Prospective	Pettit, 2020(44)	42/41	T	USA	single centre	Case-control
Gremese, 2020(29)	Sa	53/0	Italy	single centre	Prospective	Biran, 2020(45)	210/420	T	USA	multi-centre	Case-control	Potere, 2020(46)	74/74	T	Italy	single centre	Case-control
Sinha, 2020(30)	Sa	255/0	USA	single centre	Prospective	Canziani, 2020(47)	64/64	T	Italy	multi-centre	Case-control	*Ramaswamy, 2020(48)	10/10	T	USA	multi-centre	Case-control
*Gritti 2020(31)	Si	30/30	Italy	single centre	Prospective with control	Capra, 2020 (49)	62/23	T	Italy	single centre	Case-control	Rodriguez-Bano, 2020(50)	21/65	T	Spain	multi-centre	Case-control
Albertini, 2020(51)	T	22/22	France	single centre	Prospective with control	De Rossi, 2020(52)	90/68	T	Italy	single centre	Case-control	Rojas-Marte, 2020(53)	88/344	T	USA	single centre	Case-control
Antony, 2020(54)	T	80/0	USA	multi-centre	Prospective	Eimer, 2020(55)	22/22	T	Sweden	single centre	Case-control	Roomi, 2020(56)	96/97	T	USA	single centre	Case-control
Campins, 2020(57)	T	58/0	Spain	single centre	Prospective	Galvan Roman, 2020(58)	58/88	T	Spain	single centre	Case-control	*Rossi, 2020(59)	84/84	T	France	single centre	Case-control

*Carvalho, 2020(60)	T	29/24	Brazil	single centre	Prospective with control	Garcia, 2020(61)	77/94	T	Spain	single centre	Case-control	Rossotti, 2020(62)	74/148	T	Italy	single centre	Case-control
Dastan, 2020(63)	T	42/0	Iran	single centre	Prospective	Gokhale, 2020(64)	70/91	T	India	single centre	Case-control	*Roumier, 2020(65)	30/29	T	France	single centre	Case-control
Hermine, 2020(19)	T	63/67	France	multi-centre	Open-label RCT	Guaraldi, 2020(66)	179/365	T	Italy	multi-centre	Case-control	*Ruiz-Antoran, 2020(67)	268/238	T	Spain	multi-centre	Case-control
Malekzadeh, 2020(68)	T	126/0	Iran	multi-centre	Prospective	Guisado-Vasco, 2020(69)	132/475	T	Spain	single centre	Case-control	Somers, 2020(70)	78/76	T	USA	single centre	Case-control
Mikulska, 2020(71)	T	26/99	Italy	single centre	Prospective with control	Gupta, 2020(72)	433/3492	T	USA	multi-centre	Case-control	*Tsai, 2020(73)	66/66	T	USA	single centre	Case-control
Morena, 2020(74)	T	51/0	Italy	single centre	Prospective	* Hill, 2020(75)	43/45	T	USA	single centre	Case-control	* Wadud, 2020(76)	84/84	T	USA	single centre	Case-control
*Perrone 2020(77)	T	180/121	Italy	multi-centre	Single arm, open-label phase 2	Holt, 2020(78)	24/30	T	USA	single centre	Case-control	Zheng, 2020(79)	92/89	T	China	single centre	Case-control

Table 1 – Included studies with study characteristics and sample size for treatment (Tx) and control group (control) shown.
* non peer-reviewed preprint study; #, study investigating both anakinra and tocilizumab; A, anakinra; Sa, sarilumab; Si, siltuximab; T, tocilizumab

Author, year	Therapy	Adverse effects
Aouba, 2020	Anakinra	Acute respiratory failure 6 hours post dose (n=1)
Huet, 2020	Anakinra	13% in anakinra and 9% in control group had rise in liver aminotransferase
Cauchois, 2020	Anakinra	N/R
Cavalli, 2020	Anakinra	Treatment: staphylococcus epidermis (14%); deranged liver enzymes (10%). Control: bacteraemia (13%); deranged liver enzymes (31%).
* Narain, 2020	Anakinra	N/R
Benucci, 2020	Sarilumab	Nil
Della-Torre, 2020	Sarilumab	Treatment: Infections (21%); neutropenia (14%); liver enzyme increase (14%); thromboembolism (7%). Control: Infections (18%); thromboembolism (7%)
Gremese, 2020	Sarilumab	neutropenia (15%); elevated liver enzymes (11%)
Sinha, 2020	Sarilumab or Tocilizumab	bacterial infection (13%)
* Gritti 2020	Siltuximab	Nil
Albertini, 2020	Tocilizumab	elevated liver enzymes (64%)
Antony, 2020	Tocilizumab	N/R
Campins, 2020	Tocilizumab	Nil
* Carvalho, 2020	Tocilizumab	Nil
Dastan, 2020	Tocilizumab	transient diplopia (4.8%); Bell's palsy (2.4%)
Hermine, 2020	Tocilizumab	Treatment: Serious adverse events occurred in 20 (32%). 29 (43%) in the control group (P=.21)
Malekzadeh, 2020	Tocilizumab	Nil
Mikulska, 2020	Tocilizumab	N/R
Morena, 2020	Tocilizumab	elevated liver enzymes (29%), thrombocytopenia (14%), neutropenia (6%), infections (24%)
* Perrone, 2020	Tocilizumab	allergic reactions (0.4%), deranged liver enzymes (10.5%)
* Rosas, 2020	Tocilizumab	66 serious infections were reported in 62 patients (21.0%) in the tocilizumab arm and 49 in 37 patients (25.9%) in the placebo arm. Similar proportions of patients in each treatment arm experienced adverse events through the clinical cut-off date of June
Salvarani, 2020	Tocilizumab	Nil
* Sanchez-Montalva, 2020	Tocilizumab	Nil
Sciascia, 2020	Tocilizumab	Nil
Stone, 2020	Tocilizumab	Neutropenia developed in 22 patients in the tocilizumab group, as compared with only 1 patient in the placebo group (P=0.002), but serious infections occurred in fewer patients in the tocilizumab group (13 [8.1%] vs. 14 [17.3%]; P=0.03).
* Strohbehn, 2020	Tocilizumab	Treatment: bacterial infections (15.6%). Control: not reported
Toniati, 2020	Tocilizumab	septic shock (2%), gastrointestinal perforation (1%)
Biran, 2020	Tocilizumab	Treatment: secondary bacterial infection in 17%. Control: secondary bacterial infection in 13%
Canziani, 2020	Tocilizumab	HR 0.71 (95% CI 0.38-1.32) for infection; HR 0.89 (95% CI 0.39-2.06) for thrombosis; HR 1.17 (95% CI 0.47-2.92) for bleeding

Capra, 2020	Tocilizumab	Nil
De Rossi, 2020	Tocilizumab	Significant rise (from 44.3 +/- 28.3 to 103 +/- 141.3) in ALT in patients taking IV dose
Eimer, 2020	Tocilizumab	Blood stream infection: 4 (18%) in treatment group vs. 6 (27%) in control
Galvan Roman, 2020	Tocilizumab	N/R
* Garcia, 2020	Tocilizumab	N/R
Gokhale, 2020	Tocilizumab	N/R
Guaraldi, 2020	Tocilizumab	13% treated with tocilizumab diagnosed with new infections vs 4% in control (p<0.0001)
Guisado-Vasco, 2020	Tocilizumab	N/R
Gupta, 2020	Tocilizumab	Tocilizumab-treated and non-tocilizumab–treated patients experienced the following adverse events: secondary infection (140 [32.3%] vs 1085 [31.1%]); AST or ALT level elevation of more than 250 U/L (72 [16.6%] vs 452 [12.9%])
* Hill, 2020	Tocilizumab	In tocilizumab vs non tocilizumab group, there was increased sepsis (21% and 16%), ALT rise (9% vs 4%) and thrombocytopenia (12% vs 4%)
Holt, 2020	Tocilizumab	N/R
Ip, 2020	Tocilizumab	N/R
Kewan, 2020	Tocilizumab	Similar rates of hospital–acquired infections occurred in both cohorts (18% in tocilizumab and 22% in no tocilizumab cohort).
* Kimmig, 2020	Tocilizumab	tocilizumab associated with increased secondary bacterial (aOR 2.76; 95% CI 1.11-7.2) and fungal (5.6% vs. 0%, p=0.112) infections
Klopfenstein, 2020	Tocilizumab	N/R
Martinez-Sanz, 2020	Tocilizumab	N/R
* Narain, 2020	Tocilizumab	N/R
Patel, 2020	Tocilizumab	N/R
Pettit, 2020	Tocilizumab	Overall infection rate was similar (16.2% tocilizumab vs. 17.5% control), but late on-set infections occurred in more tocilizumab patients (23% vs 8%; p=0.013). In tocilizumab cohort, 26% experienced an increase to >5 times upper limit normal of LFTs
Potere, 2020	Tocilizumab	Nil
* Ramaswamy, 2020	Tocilizumab	N/R
Rodriguez-Bano, 2020	Tocilizumab	secondary bacterial infection similar in both groups (tocilizumab 12.5% vs. 10.3% control; p=0.57)
Rojas-Marte, 2020	Tocilizumab	Bacteraemia was more common in the control group (24% vs. 13%, P=0.43), while fungemia was similar for both (3% vs. 4%, P=0.72)
Roomi, 2020	Tocilizumab	N/R
* Rossi, 2020	Tocilizumab	N/R
Rossotti, 2020	Tocilizumab	infectious complication in 32.4%
* Roumier, 2020	Tocilizumab	Tocilizumab group: hepatic cytolysis (7%), ventilator acquired pneumonia (3%)
* Ruiz-Antoran, 2020	Tocilizumab	32.6% in tocilizumab vs. 30.3% in control had increase in liver enzymes. Bacteraemia in 1 patient (0.4%)
Somers, 2020	Tocilizumab	higher rate of superinfection in tocilizumab group (54% vs 26%; p<0.001)
* Tsai, 2020	Tocilizumab	N/R
* Wadud, 2020	Tocilizumab	N/R
Zheng, 2020	Tocilizumab	N/R

Table 2– Treatment related adverse events. Adverse events for drug under study reported. Adverse events for control population reported where applicable. * non peer-reviewed preprint study